$1.57
3.97% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US09077A1060
Symbol
BMEA
Sector
Industry

Biomea Fusion Inc Stock price

$1.57
-0.15 8.72% 1M
-4.71 75.00% 6M
-2.31 59.54% YTD
-11.05 87.56% 1Y
-4.97 75.99% 3Y
-17.03 91.56% 5Y
-17.03 91.56% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.06 3.97%
ISIN
US09077A1060
Symbol
BMEA
Sector
Industry

Key metrics

Market capitalization $58.99m
Enterprise Value $31.06m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.05
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-132.72m
Free Cash Flow (TTM) Free Cash Flow $-113.86m
Cash position $35.86m
EPS (TTM) EPS $-3.55
P/E forward negative
Short interest 38.19%
Show more

Is Biomea Fusion Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Biomea Fusion Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Biomea Fusion Inc forecast:

4x Buy
67%
2x Hold
33%

Analyst Opinions

6 Analysts have issued a Biomea Fusion Inc forecast:

Buy
67%
Hold
33%

Financial data from Biomea Fusion Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 1.74 1.74
53% 53%
-
-1.74 -1.74
53% 53%
-
- Selling and Administrative Expenses 22 22
24% 24%
-
- Research and Development Expense 107 107
4% 4%
-
-131 -131
2% 2%
-
- Depreciation and Amortization 1.74 1.74
53% 53%
-
EBIT (Operating Income) EBIT -133 -133
3% 3%
-
Net Profit -129 -129
1% 1%
-

In millions USD.

Don't miss a Thing! We will send you all news about Biomea Fusion Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biomea Fusion Inc Stock News

Neutral
GlobeNewsWire
6 days ago
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that preliminary clinical data from the Phase I COVALENT-103 trial of BMF-500 in adults with acute leukemia (AL) were selected for a poster presentation at the European Hematology Association (EHA) 2025 Congress, taking pl...
Neutral
GlobeNewsWire
15 days ago
Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients that are currently uncontrolled on a GLP-1 based therapy Biomea's next generation oral GLP-1 receptor agonist (BMF-650) filing for IND All other clinical and preclinical activities...
Neutral
GlobeNewsWire
about 2 months ago
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on March 23, 2025, the compensation committee of Biomea's board of directors granted two new employees non-qualified stock options to purchase an aggregate of 30,000 shares of the Company's common s...
More Biomea Fusion Inc News

Company Profile

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

Head office United States
CEO Michael Hitchcock
Employees 106
Founded 2017
Website biomeafusion.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today